IR NewsInvestors

Investors
2026 IR News

IR News 2026

Nov 06, 2026

FINANCIALS

FY2026 Q3 Presentation

Nov 06, 2026

FINANCIALS

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2026

Nov 05, 2026

ANNOUNCEMENT

Carna announces acceptance of two posters on docirbrutinib for presentation at the 68th ASH Annual Meeting

Aug 06, 2026

FINANCIALS

FY2026 Q2 Presentation

Aug 06, 2026

FINANCIALS

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2026

Jul 21, 2026

ANNOUNCEMENT

Carna Announces FDA Orphan Drug Designation Granted to monzosertib (AS-0141) for Acute Myeloid Leukemia

Jun 15, 2026

ANNOUNCEMENT

Expanded Phase 1b Study Data for Docirbrutinib Demonstrate Robust Response and Favorable Safety Profile at EHA 2026

May 13, 2026

ANNOUNCEMENT

Carna to Present Updated Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2026

May 08, 2026

ANNOUNCEMENT

Publication of Preclinical and Early Clinical Data Demonstrating Best-in-Class, Pan-Mutant Activity of BTK Inhibitor Docirbrutinib

May 08, 2026

FINANCIALS

FY2026 Q1 Presentation

May 08, 2026

FINANCIALS

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2026

Mar 18, 2026

ANNOUNCEMENT

Carna to Present Preclinical Findings on Monzosertib‑Induced Cancer Cell Death at AACR Annual Meeting

Feb 10, 2026

ANNOUNCEMENT

Corporate Presentation Feb. 2026

Feb 10, 2026

FINANCIALS

FY2025 Presentation

Feb 10, 2026

FINANCIALS

Consolidated Financial Results for the Year Ended December 31, 2025